Zeo ScientifiX, Inc. (ZEOX): Operating Income
-$5.39M
Year ended 2025-10-31
-$4.13M
Trailing 12 months to 2026-04-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | -$5.39M | n/m | 2026-01-29, From 2024-11-01 |
| 2024-10-31 | -$5.32M | n/m | 2026-01-29, From 2023-11-01 |
| 2023-10-31 | -$6.77M | n/m | 2025-01-29, From 2022-11-01 |
| 2022-10-31 | -$8.84M | n/m | 2024-01-29, From 2021-11-01 |
| 2021-10-31 | -$12.74M | n/m | 2023-02-14, From 2020-11-01 |
| 2020-10-31 | -$12.44M | n/m | 2022-02-14, From 2019-11-01 |
| 2019-10-31 | -$1.78M | n/m | 2021-02-08, From 2018-11-01 |
| 2018-10-31 | -$3.49M | n/m | 2020-10-16, From 2017-11-01 |
| 2017-10-31 | -$8.64M | n/m | 2020-03-06, From 2016-11-01 |
| 2016-10-31 | -$1.04M | n/m | 2018-11-01, From 2015-11-01 |
| 2015-10-31 | -$744.3K | n/a | 2017-07-07, From 2014-11-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$5.39M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$147.06M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$208.35M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$62.92M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$147.70M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$190.77M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$664.57M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$42.09M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$7.19M | n/m |
Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗